Description

Retatrutide

Investigational Peptide Compound | Laboratory & Analytical Research

Retatrutide, also known by the development code LY3437943, is a synthetic peptide compound being investigated as a triple agonist of the GIP, GLP-1, and glucagon receptors. Lilly is currently evaluating retatrutide in Phase 3 clinical programs.

Retatrutide is relevant to research involving peptide chemistry, receptor signaling, metabolic biology, analytical characterization, formulation science, and comparative incretin research.

Retatrutide Research Profile

Retatrutide is a modified peptide designed to interact with three hormone receptors: GIPR, GLP-1R, and the glucagon receptor (GCGR). Its structure includes a 39-residue peptide backbone and a lipid-containing modification that contributes to its molecular characteristics.

Laboratory research may investigate the compound’s molecular identity, receptor activity, analytical properties, stability, purity, and formulation characteristics.

Retatrutide Chemical Information

Specification Details
Product Name Retatrutide
Development Code LY3437943
Compound Type Synthetic lipidated peptide
Peptide Length 39 residues
Molecular Formula C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight Approximately 4,731 g/mol
CAS Number 2381089-83-2
Receptor Profile GIP / GLP-1 / Glucagon triple agonist
Research Classification Investigational peptide compound

Current chemical-reference sources report the formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight around 4,731 g/mol, and CAS 2381089-83-2.

Retatrutide Research Applications

Retatrutide may be investigated in controlled laboratory research involving:

  • Peptide chemistry
  • GIP receptor research
  • GLP-1 receptor research
  • Glucagon receptor research
  • Receptor-signaling studies
  • Metabolic biology
  • Molecular characterization
  • Analytical chemistry
  • Purity and assay testing
  • Peptide stability research
  • Formulation research
  • Comparative peptide studies

Key Characteristics

Triple-Receptor Research

Retatrutide is being investigated as a single molecule that activates GIP, GLP-1, and glucagon receptors, providing a defined model for studying multi-receptor signaling.

Modified Peptide Structure

Retatrutide contains a 39-residue peptide backbone together with non-standard residues and a lipid-containing side-chain modification. These structural features are important when performing analytical identification and characterization.

Analytical Characterization

Research workflows may evaluate identity, molecular mass, purity, concentration, stability, degradation products, and formulation consistency using appropriate laboratory methods.

Research Documentation

Batch-specific documentation can provide information about peptide identity, purity, assay, batch number, and analytical testing.

Retatrutide Product Specifications

Product Name: Retatrutide
Development Code: LY3437943
Peptide Length: 39 residues
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: Approximately 4,731 g/mol
CAS Number: 2381089-83-2
Compound Type: Synthetic lipidated peptide
Intended Application: Laboratory and analytical research

Available Product Variants

Your current product page lists these package variants: 5mg × 10 vials, 10mg × 10 vials, 15mg × 10 vials, 20mg × 10 vials, 30mg × 10 vials, 40mg × 10 vials, 50mg × 10 vials, and 60mg × 10 vials.

Quality & Documentation

Depending on the supplied material, product documentation may include:

  • Peptide identity
  • Sequence or structural information
  • Purity or assay
  • Molecular-weight information
  • Batch or lot number
  • Certificate of Analysis (COA)
  • Analytical testing
  • Stability information
  • Product specifications

The actual product label and batch-specific COA should be treated as the definitive source for the supplied material.

Retatrutide Research Status

Retatrutide remains an investigational compound. Lilly’s September 2026 information states that retatrutide is still being studied in Phase 3 /product/retatrutide/ clinical trials and is not currently approved by the FDA. Lilly has announced plans to submit a Biologics License Application to the FDA in 2027.

Results reported from clinical trials should not be used to represent a separately supplied research material as an approved medicine or to establish its quality, safety, or efficacy.

Important Research Information

Retatrutide is a biologically active investigational peptide. Product identity, purity, concentration, formulation, and batch characteristics should be verified using the applicable manufacturer documentation and analytical testing.

This product information is provided for scientific, analytical, compound-identification, and legitimate laboratory research purposes. It does not provide dosing, administration, treatment, or therapeutic-use instructions.